US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Provet Cloud Launches Pilot Program with Prominent U.S. Veterinary Group, Expanding North American Footprint

Denver, CO – December 2024 – Provet Cloud, the cloud-based veterinary practice management software from Nordhealth, today announced a pilot program with a prominent U.S. veterinary group operating more than 200 locations. Although Provet Cloud already supports approximately 150 clinics in the United States, this marks its first partnership with a large corporate veterinary organization in North America—further solidifying the company’s growing footprint in the region. Provet Cloud serves over 15,000 veterinarians in more than 2,500 veterinary clinics and hospitals worldwide, including

Nordhealth AS: Q3/2024 results presentation

Please find attached the presentation of Nordhealth AS Q3/2024 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Laine on the 12th of November 2024 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88457477200 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Laine, CFO mari.laine@nordhealth.com +358 46 8765 233

Nordhealth AS - Invitation to Q3 2024 presentation

Nordhealth will report and present its Q3 2024 results on Tuesday the 12[th] of November 2024.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Laine on the 12[th] of November at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88457477200 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q3/2024 will be available on 12 November 2024 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR  website https://nordhealth.com/investor/news-

Nordhealth AS: Q2 and first half 2024 interim financial report

Please find attached the Q2 presentation and interim financial report of Nordhealth AS first half 2024 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Laine on the 20[th] of August 2024 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/84944459012 The presentation will be recorded and made available on www.nordhealth.com. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Laine, CFO mari.laine@nordhealth.com

Nordhealth AS - Invitation to Q2 2024 presentation

Nordhealth will report and present its Q2 2024 results on Tuesday the 20[th] of August 2024.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Laine on the 20[th] of August at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/84944459012 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q2/2024 and the 1H/2024 interim financial report will be available on 20 August 2024 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR  website

Nordhealth Announces Appointment of Karan Wallia as CEO of Therapy business unit

Helsinki, Finland - July 30, 2024 - Nordhealth, a leading provider of cloud-based healthcare SaaS solutions in Europe, is pleased to announce the appointment of Karan Wallia as the new CEO of the Therapy Business Unit, effective September 2nd 2024. Karan Wallia brings a wealth of experience from his previous roles, including Senior Vice President of Product & Ecosystem at SmartRecruiters and Director of Product at Booking.com. His proven track record in driving growth, product innovation, and strategic execution will be invaluable as Nordhealth continues to expand its footprint in the

Nordhealth Achieves EBITDA - CAPEX Breakeven Ahead of Schedule

Helsinki, Finland - July 18, 2024 - Nordhealth is pleased to announce that it has achieved EBITDA-CAPEX breakeven in Q2 2024, excluding one-off, non-recurring items. This milestone, initially projected for Q1 2025 as outlined in the Q4 2023 Investor Presentation on March 5, 2024, and reaffirmed in the 2023 Annual Report on April 12, 2024, has been reached ahead of schedule. Preliminary figures indicate that Nordhealth's EBITDA-CAPEX, excluding one-off, non-recurring items, will be slightly positive in Q2 2024. However, as planned, the company does not expect to maintain EBITDA-CAPEX

Annual General Meeting in Nordhealth AS

The Annual General Meeting (the "AGM") of Nordhealth AS (the "Company") was held on 30 May 2024 at 10:00 hours (CET). The minutes of the AGM are attached, as well as the attendance list and voting protocol. All resolutions were approved in accordance with the proposal from the board of directors including, inter alia, a board authorization to increase the share capital with up to NOK 12,028,761.90 by issuance of new shares and to acquire treasury shares for an amount of up to NOK 12,028,761.90. These authorizations will replace the previous authorizations issued at the annual general

Notice of Annual General Meeting of Nordhealth AS

16 May 2024 – Notice is given to the shareholders of Nordhealth AS (the "Company") that the Annual General Meeting will be held on 30 May 2024 at 10:00 hours (CET).The meeting will be conducted as a virtual meeting only. Shareholders may also participate by means of advance votes or provide a proxy with voting instructions. Pre-registration is needed for attending the meeting, see Appendix 1 of the attached notice. Deadline for the pre-registration and registration of advance votes and proxies is 28 May 2024 at 16:00 hours (CET). For further information, please contact: Charles

Nordhealth AS: Q1/2024 results presentation

Please find attached the presentation of Nordhealth AS Q1/2024 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 14th of May 2024 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88305835582 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Orttenvuori, CFO mari.orttenvuori@nordhealth.com +358 46 8765 233

Nordhealth AS - Invitation to Q1 2024 presentation

Nordhealth will report and present its Q1 2024 results on Tuesday the 14[th] of May 2024.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 14[th] of May at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88305835582 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q1/2024 will be available on 14 May 2024 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR  website https://nordhealth.com/investor/news-and-

Nordhealth AS: Q4 and second half 2023 interim financial report

Please find attached the Q4 presentation and interim financial report of Nordhealth AS second half 2023 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 5th of March 2024 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/83057714357 The presentation will be recorded and made available on www.nordhealth.com. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200  Mari Orttenvuori, CFO mari.orttenvuori@

Nordhealth AS - Invitation to Q4 2023 presentation

Nordhealth will report and present its Q4 2023 results on Tuesday the 5[th] of March 2024.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 5[th] of March at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/83057714357 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q4/2023 and the 2H/2023 interim financial report will be available on 5 March 2024 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR  website

Nordhealth Finland receives ISO/IEC 27001:2022 certification, applying highest standards of security to customer data

Helsinki, 9th January 2024: Nordhealth , the Helsinki-based healthcare software company supporting over 55,000 healthcare professionals worldwide, has announced that it has officially received ISO/IEC 27001 certification in Finland, the international standard for information security and privacy. The certification underscores Nordhealth’s dedication to safeguarding the sensitive data that it handles every day on behalf of its software users, including privately identifiable information and medical records of countless pet-owner clients and their pets.

Nordhealth AS - Primary insider notices

Helsinki, Finland, 29 December 2023: Charles MacBain, the CEO and primary insider of Nordhealth AS (the "Company"), has today exchanged 5,505,319 class A shares in the Company for an equal number of class B shares. The exchange was executed in two separate transactions with family members who held B shares. Following the transactions, Charles MacBain owns 268,187 class A shares in the Company. In addition, he holds 29 794 638 class B shares, in total 30,062,825 shares. Please refer to the attached notifications in accordance with the Market Abuse Regulation article 19 for further

Nordhealth AS - Primary insider notices

Helsinki, Finland, 22 December 2023: Charles MacBain, the CEO and a primary insider of Nordhealth AS (the "Company"), has today sold 1,650,316 class A shares in the Company at a price of NOK 21.34 per share, in two separate transactions to family members who have agreed to vote and dispose of the shares with Charles MacBain. Following the transactions, Charles MacBain owns 5,773,507 class A shares in the Company. In addition, he holds 24,289,319 class B shares, in total 30,062,826 shares. Please refer to the attached notifications in accordance with the Market Abuse Regulation article

Nordhealth AS: Results of Share Buy Back

Reference is made to the stock exchange announcement on 30 November 2023, where Nordhealth AS (the "Company") launched an offer to purchase up to 1,000,000 of its own shares through a reverse book building process (the "Offering"). The application period expired at 16:30 hours (CET) on 6 December 2023. Following the end of the application period, the Company has resolved to buy 992,624 shares at a price of NOK 23.00 per share, which equals approximately NOK 22.8 million in total. All offers to sell shares with limits at or below NOK 23.00 have been allocated in full. Allocation

Nordhealth AS: Initiating Offer To Buy Back Own Shares

(November 30[th], 2023) Nordhealth AS (the «Company») hereby launches an offer to purchase up to 1,000,000 of its own shares (the «Offering»). The Offering will be carried out as a reversed book-building process where the Company, through Carnegie AS («Carnegie»), will receive offers for desired volume(s) for sale from the shareholders.All shareholders in the Company are invited to sell shares in the Offering, subject to the restrictions set out herein. The Company has mandated Carnegie as bookrunner for the Offering and shareholders with interest to sell shares may contact Carnegie via

Nordhealth AS – Primary insider notice

Helsinki, Finland, 16 November 2023: Three Plus Group Luxembourg SA ("TPG"), a majority owned company and close associate of Charles MacBain, CEO and primary insider of Nordhealth AS (the "Company"), has today entered into an agreement to transfer 4,904,387 class A shares and 29,794,638 class B shares, in total 34,699,025 shares held by TPG in the Company to Boxwood Holdings Ltd ("Boxwood"), a company which is also majority owned and a close associate of Charles MacBain. Simultaneously, Boxwood has approved the subsequent transfer of such Company shares to the Boxwood shareholders, namely

Nordhealth AS – Primary insider notice

Helsinki, Finland, 16 November 2023: Charles MacBain, the CEO and a primary insider of Nordhealth AS (the "Company"), has today purchased 1,948,077 class A shares in the Company at a price of NOK 23.50 per share. Following the transaction, Charles MacBain owns 7,423,823 class A shares in the Company. In addition, he holds 4,904,387 class A shares and 29,794,638 class B shares, in total 34,699,025 shares indirectly, through Three Plus Group Luxembourg SA. Please refer to the attached notification of trading for further details. For further information, please contact: Charles

Nordhealth AS: Q3/2023 results and CMD presentation

Please find attached the Q3/2023 results and presentation for the CMD.The results will be presented in a live event that can also be participated through a live webcast and subsequent Q&A session on the 14th of November 2023 at 10:00 CET. CEO Charles MacBain, CFO Mari Orttenvuori and GM Veterinary Valter Pasanen will hold the presentation. For those attending through the live webcast, please access through this link: https://channel.royalcast.com/landingpage/hegnarmedia/20231114_5/ The webcast will be available after the event on our website at www.nordhealth.com.  For further

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe